Comprehensive India Pharma Market Report Launching at CPHI India 2014

CPHI India, organised by UBM Live, announces that it will be releasing a comprehensive India pharma market report at CPHI India 2014 (2–4 December 2014 in Mumbai). The report, conducted with the help of research partner Global Business Reports, will include thought-provoking analysis from key industry players; for example, Cipla, Piramal, Sun, Lupin, Aurobindo and Biocon, Government bodies (IBEF/Pharmexcil) and explore new growth areas emerging across the country.

Now the tenth largest economy in the world and with global exports of around US$15 billion during the last 12 months, India is an innovation hub and a well-known focal point of the pharmaceutical industry and McKinsey and Company forecast a staggering total value of US$45 billion by 2020. Around 220 countries are sourcing pharma products from India, with the top 20 of India’s pharmaceutical companies contributing to almost two-thirds of the country’s total exports.

Those companies are further expected to increase capital expenditure (capex) by 40 per cent to over US$8.3 billion by 2017–2018. India is constantly looking to increasingly match high quality Western standards, whilst maintaining lower manufacturing costs, showcasing the Indian pharma markets unique position and providing an optimum investment platform for international companies.

The CPHI India report will feature a robust analysis of the Indian pharma market and include significant contributions from 98 companies and all major Indian manufacturers, evaluating conditions for both foreign and domestic companies. Printed copies of the detailed 100+ page report will be available at CPHI India along with a media-ready version produced and launched to media at the event, including an overview of trends contained within the full report.

Another new initiative is the introduction of the CPHI Global Angels charity campaign, which was first launched earlier this year at CPHI Worldwide. It is being rolled out across CPHI’s global portfolio and is designed to call on the pharma community to lend its support to this global charity that is transforming disadvantaged communities around the world.

"It’s a really exciting time to be working across this leading pharma market as the global demand for Indian made drugs continues to rise, particularly with Western economies looking to further expand their use of generics. Meet the movers and shakers in India’s pharma machinery, technology, ingredients, outsourcing and bio-pharma industry for a competitive advantage that will help grow your business.

“With the highest number of USFDA-approved facilities outside of the US, it is unsurprising that India has seen a huge growth in the number of exports. India’s economy is thriving as the demand for generics is on the rise and companies are looking to drive down manufacturing costs. India is well positioned to accommodate increased demand, providing expertise in development and manufacturing. This is an amazing time for the CPHI community to gather in Mumbai during the CPHI India, a world-class pharma event that continues to provide an essential platform for international and domestic suppliers & buyers to break into the market. There has never been a better time to invest in such a dynamic and thriving economy and we look forward to another successful CPHI India,” said Chris Kilbee, Group Director Pharma at UBM Live.